<DOC>
	<DOCNO>NCT02395640</DOCNO>
	<brief_summary>This study design compare efficacy safety XELOX regimen EOX regimen first-line treatment advance gastric cancer patient .</brief_summary>
	<brief_title>The Comparison XELOX EOX First-line Treatment Advanced Gastric Cancer</brief_title>
	<detailed_description>This study design compare efficacy safety XELOX regimen EOX regimen first-line treatment advance gastric cancer patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Major inclusion criterion histologically proven adenocarcinoma gastroesophageal junction , stomach locally advance ( inoperable ) metastatic measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group performance status 0 2 adequate renal , hepatic , hematologic function Major exclusion criterion previous chemotherapy radiotherapy ( unless adjuvant setting ) uncontrolled cardiac disease , clinically significant , uncontrolled coexisting illness previous concurrent cancer accumulate dose Epirubicin exceed 300mg/m2 HER2 positive willing use trastuzumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>